Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Fzata
AddedFeb 16, 2024
UpdatedJun 18, 2026
Fzata

Fzata

Seed

Fzata, a noble biotech firm, pioneers in oral biologics and gastrointestinal drug development using BioPYM technology.

HQ
Halethorpe, MD, US
Founded
2015
Overview
Compare
Fundraising
Employees
Website

Fzata, founded with a mission to revolutionize oral biologics, focuses on developing innovative treatments for gastrointestinal-related disorders. The company leverages its proprietary Bioengineered Probiotic Yeast Medicines (BioPYM) platform, which uses live yeast to create transformative biotherapeutics. With a vision to enhance safety, efficacy, and access to biologics, Fzata aims to address unmet medical needs in the gastrointestinal market.

Notable achievements include securing $17 million in non-dilutive funding from the National Institutes of Health (NIH). Fzata has been recognized as an NIH Innovation Zone Company and represents Maryland at BIO conventions. The company's pioneering work in BioPYM technology positions it as a leader in the biotech industry, contributing significantly to advancements in oral biologics and gastrointestinal therapies.

Fzata - Similar Companies

Faze Medicines logo

Faze Medicines

fazemed.com

ZBiotics logo

ZBiotics

zbiotics.com

Zymeron logo

Zymeron

zymeron.com

Federation Bio logo

Federation Bio

federation.bio

Petri Bio logo

Petri Bio

petribio.com

Kiwi Biosciences logo

Kiwi Biosciences

fodzyme.com

Felix Biotechnology logo

Felix Biotechnology

Granata Bio logo

Granata Bio

granata.bio

Bond Biosciences logo

Bond Biosciences

bond.bio

Fauna Bio logo

Fauna Bio

faunabio.com

Petragen logo

Petragen

petragen.com

Zyngenia logo

Zyngenia

Zeteo Tech logo

Zeteo Tech

zeteotech.com

GenieBiome logo

GenieBiome

Zenomics logo

Zenomics

Fzata - Quick Facts

Who are Fzata's competitors?

Companies similar to Fzata include Faze Medicines, ZBiotics, Zymeron and Federation Bio.

When was Fzata founded?

Fzata was founded in 2015.

Where is Fzata's headquarters located?

Fzata's headquarters is located in Halethorpe, MD, US.

When was Fzata's last funding round?

Fzata's most recent funding round was for $1M (USD) in January 2016.

How much has Fzata raised to-date?

As of Jan 1, 2016, Fzata has raised a total of $1M (USD).

How many employees does Fzata have?

Fzata has 9 employees as of Feb 4, 2024.

Fzata - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Biotherapeutics
Tags
  • Biotech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified